Quick summary of $PRME July 2025 presentation 👇🏻: • $PRME is shifting from platform validation to imminent clinical trials. • The first ever human data (program PM359 for CGD) confirmed prime editing is safe and effective in humans. • Lead liver programs: -Wilson’s Disease

This weekend, members from our #ATTR team will be at the #ESCCongress. HCPs: Don’t miss our symposium on Monday, chaired by Dr. Julian Gillmore, discussing all things #amyloidosis and advancements in the field. #ESCCongress #WCCardio

Magnitude 2, the pivotal Ph. 3 for ATTR-PN from $NTLA, added one new site in Argentina today. Up to 15 sites which should go fast considering only 50 are needed. Sites per country 3 in Argentina 🇦🇷 1 in Australia 🇦🇺 4 in Brazil 🇧🇷 1 in New Zealand 🇳🇿 2 in Singapore 🇸🇬 3 in

Enrollment completed in 3 months $NTLA “Observers of the field said they’ve never seen that level of interest other than the very first time the first therapies were offered to these patients years ago.” 👀 “In a single month, 41 patients presented themselves to be screened.”

$NTLA Stock reactions of other biotech companies post durability data:

Huntington’s disease has been treated successfully for the first time in a gene therapy trial

A single dose of a new cancer drug made a brain tumor almost disappear – in just five days. Doctors at Massachusetts General Hospital reported “dramatic and rapid” tumor regression in the first patients treated with a next-generation form of CAR T-cell therapy for glioblastoma,

It will be very interesting to see the updates (hopefully very promising) on the FT836 trial. $FATE

$FATE abc7.com/amp/post/uci-h…

x.com/i/article/2040…